Lemborexant

For Print（311KB） July 2, 2026 Full text（311KB） Our news releases are intended to disclose corporate information and are not intended for the promotion or advertising of prescription pharmaceuticals or investigational products, nor are they intended to provide medical advice. Please note that the information contained in news releases is current as of the date of publication.

Eisai lays out growth blueprint anchored by LeqembiUN plan makes vaccines a frontline weapon against superbugsEisai lays out growth blueprint anchored by LeqembiEisai unveiled a new three-year growth strategy that aims to lift annual revenue to JPY 1 trillion ($6.3 billion) and core operating profit to JPY 90 billion by fiscal 2028, driven largely by expansion of its Alzheimer's treatment Leqembi (lecanemab), as well as its insomnia therapy Dayvigo (lemborexant) and cancer drug Lenvima (lenvatinib).Leqembi is projected to generate JPY 300 billion in annual revenue by fiscal 2028, up from JPY 88 billion in fiscal 2025. Eisai recently projected Leqembi sales of JPY 143.5 billion for fiscal 2026, spurred by efforts to improve diagnosis-to-treatment pathways, as well as an anticipated US approval in August for the drug's subcutaneous auto-injector formulation as a starting dose for early Alzheimer's patients. Eisai also anticipates Dayvigo will bring in annual sales of JPY 100 billion by fiscal 2028, versus JPY 64.3 billion in fiscal 2025. Cancer medicine Lenvima is expected to remain a major contributor despite looming generic pressure, with Eisai forecasting JPY 250 billion in sales by fiscal 2028 compared with JPY 342.5 billion in fiscal 2025.Citi analyst Hidemaru Yamaguchi described Eisai's strategy as "a transition from a bullish stance to a conservative one," while also citing concerns about "anticipated deterioration in the product mix, which is somewhat negative."1.00 JPY = 0.00629275 USDUN plan makes vaccines a frontline weapon against superbugsIn the UN's updated Global Action Plan on Antimicrobial Resistance (GAP-AMR) 2026-2036, vaccination – within a broader "prevention-first" approach – has been elevated from a supporting measure to a much more central pillar for fighting drug-resistant superbugs. This second edition of the strategy builds on the first GAP-AMR adopted by the World Health Assembly in 2015.The new plan directs countries to strengthen national immunisation programmes specifically to reduce preventable infections and the need for antibiotics, arguing that prevention is a key strategy for slowing the rise of antimicrobial resistance.Additionally, the plan suggests that the traditional volume-based sales model for antibiotics is unsustainable. "Research and development may be incentivised through a mix of 'push' mechanisms that lower the costs and risks of new antimicrobial or product development, and 'pull' incentives that…delink revenues from sales volumes, thereby encouraging innovation while safeguarding the appropriate use and disposal of antimicrobials."